Time for a paradigm shift: The future of the PBM industry


 

When pharmacy benefit managers entered the market, they promised easy claim management and a rational way to control the cost of life-saving medications. But prescription drug costs have continued to rise. Manufacturer rebates have become increasingly opaque. And the PBM channel has concentrated enormous market power in the hands of a few firms. Patients, payers, and legislators are questioning the PBM value proposition, and subjecting it to new scrutiny with each drug price hike.  

To survive, the industry needs an injection of creativity and innovation. It’s time for change. Join Mesfin Tegenu and leading healthcare finance experts for an in-depth discussion of the strategies and solutions in the prescription drug market. 

In this webinar, industry experts discuss:

  • The role of rebates in the evolution of the PBM industry  

  • The concept of value-based drug pricing to encourage fair access 

  • The recent and sudden increase of legislative activities intended to regulate the industry

 
 

Webinar now available on demand.

Fill out the form below to watch.

Meet the Speakers

 

 
 
Perry Cohen CEO, The Pharmacy Group

Perry Cohen
CEO, The Pharmacy Group

 
Scott Howell Vice President & Chief Strategy Officer for US Pharmaceuticals, Novartis

Scott Howell
Vice President & Chief Strategy Officer for US Pharmaceuticals, Novartis

 
John O’Brien Former Senior Advisor to the Secretary for Drug Pricing, HHS

John O’Brien
Former Senior Advisor to the Secretary for Drug Pricing, HHS